Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial (vol 21, 156, 2021)

被引:19
|
作者
Zhang, Xiaoqiang [1 ]
Li, Shuang [1 ]
Liu, Jing [1 ]
机构
[1] Mengcheng Cty 1 Peoples Hosp, Dept Anaesthesiol, Mengcheng 233500, Anhui, Peoples R China
关键词
Anaesthesia; Benzodiazepine; Hysteroscopy; Propofol; Remifentanil; Remimazolam besylate;
D O I
10.1186/s12871-021-01390-x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues. This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteroscopy. Methods: Patients undergoing hysteroscopy were randomly assigned to either the remimazolam (Group R) or the propofol group (Group P). Group R was administered an induction dose of 0.2 mg/kg and a maintenance dosage of 1.0 mg/kg/h. In Group P, propofol was started at 1.5–2.0 mg/kg and then maintained at 3.0–6.0 mg/kg/h. After remimazolam besylate or propofol induction, remifentanil was infused using a target-controlled infusion system with a target concentration of 1.5 ng/ml and titrated during the procedure. The incidence rates of injection pain, low oxygen saturation (SpO2) and adverse effects in both groups were compared. Results: Eighty-two patients were included in this study. The incidence of adverse events in Group R (3.7%) was significantly lower than that in Group P (36.6%) (p < 0.001). The incidence of injection pain in Group P (80.5%) was much higher than that in Group R (2.4%) (p < 0.001). The incidence of other adverse events, such as low SpO2, bradycardia, and hypotension in Group R was lower than that in Group P (p < 0.05). Conclusions: Remimazolam besylate proves to be a safer alternative for anesthesia during hysteroscopy. Moreover, adverse events caused by propofol, such as low SpO2 and injection pain, are largely avoided. Trial registration: This study was approved by the Clinical Research Ethics Committee of Mengcheng County No. 1 People’s Hospital (2020MYL20003) and registered at http://www.chictr.org.cn (15/09/2020, ChiCTR-2000038252). The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. © 2021, The Author(s).
引用
收藏
页数:2
相关论文
共 50 条
  • [21] Efficacy and safety of remimazolam besylate in patients with obesity undergoing painless colonoscopy: a prospective, double-blind, randomized controlled trial
    Deng, Lei
    Zhou, Rui
    Jiang, Wencai
    Zhai, Wenhu
    Chen, Xuemeng
    Xia, Leqiang
    Xiong, Chao
    Zhou, Yukai
    Zhang, Xianjie
    Peng, Yanhua
    SIGNA VITAE, 2024, 20 (07) : 76 - 85
  • [22] The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial
    Chen, Shaohui
    Wang, Jin
    Xu, Xiaohan
    Huang, Yuguang
    Xue, Shanfu
    Wu, Anshi
    Jin, Xiaoju
    Wang, Qiang
    Lyu, Jianrui
    Wang, Sheng
    Li, Yujuan
    Yu, Yonghao
    Ai, Dengbin
    Luo, Ailin
    Min, Su
    Li, Lin
    Zou, Xiaohua
    Liu, Jin
    Lv, Peilin
    Chai, Xiaoqin
    Sun, Xude
    Zhao, Zhibin
    Zhang, Jiaqiang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (08): : 4594 - 4603
  • [23] Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
    Deng, Yang
    Qin, Zhijun
    Wu, Qianyun
    Liu, Linsong
    Yang, Xi
    Ju, Xuan
    Zhang, Ying
    Liu, Lei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 2439 - 2451
  • [24] Prospective Randomized Controlled Trial Comparing Anesthetic Management With Remimazolam Besylate and Flumazenil Versus Propofol During Awake Craniotomy Following an Asleep-awake-asleep Method
    Sato, Takehito
    Ando, Takahiro
    Ozeki, Kanako
    Asano, Ichiko
    Kuwatsuka, Yachiyo
    Ando, Masahiko
    Motomura, Kazuya
    Nishiwaki, Kimitoshi
    JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2025, 37 (01) : 40 - 46
  • [25] Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial
    Wang, Chunyan
    Gao, Yangzheng
    Li, Jie
    Zhang, Linlin
    Li, Qing
    Li, Yize
    Lu, Yuechun
    Sun, Jiangang
    Zhang, Yang
    Cheng, Yaobei
    Zhang, Shidong
    Wang, Guolin
    Yu, Yonghao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [26] Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial
    Matsuyuki Doi
    Kiyoshi Morita
    Junzo Takeda
    Atsuhiro Sakamoto
    Michiaki Yamakage
    Toshiyasu Suzuki
    Journal of Anesthesia, 2020, 34 : 543 - 553
  • [27] Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial
    Doi, Matsuyuki
    Morita, Kiyoshi
    Takeda, Junzo
    Sakamoto, Atsuhiro
    Yamakage, Michiaki
    Suzuki, Toshiyasu
    JOURNAL OF ANESTHESIA, 2020, 34 (04) : 543 - 553
  • [28] Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial (Vol 16, pg 2439, 2022)
    Deng, Y.
    Qin, Z.
    Wu, Q.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 2681 - 2681
  • [29] Efficacy of progressive muscle relaxation training in migraine prophylaxis -: a single-centre, randomized, controlled trial
    Wöber, C
    Gharabaghi, M
    Huber, M
    Zuckermann, A
    Maly, J
    Wessely, P
    CEPHALALGIA, 2005, 25 (10) : 946 - 947
  • [30] Effects of adding low-dose esketamine to sufentanil and propofol sedation during cervical conization: a single-centre, randomized controlled trial
    Si, Jiguo
    Li, Xiaomin
    Wang, Yuqi
    Feng, Nianhai
    Cui, Min
    BMC ANESTHESIOLOGY, 2024, 24 (01)